113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details

臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

18 trials found

diseases per page:

Showing 1 to 10 of 18 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000122-10-GR (EUCTR)	25/11/2021	13/10/2021	A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)	A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: NS-065/NCNP-01 INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	74	Phase 3	United States;Hong Kong;Taiwan;Greece;Spain;Ukraine;Turkey;Chile;Russian Federation;United Kingdom;I ...
2	EUCTR2019-002076-13-NO (EUCTR)	08/09/2021	18/02/2021	This is a randomized, double-blind, Placebo-controlled sudy to evaluate the Efficacy and Safety of V ...	A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy an ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: NS-065/NCNP-01 INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	74	Phase 3	United States;Hong Kong;Taiwan;Greece;Spain;Ukraine;Turkey;Chile;Russian Federation;United Kingdom;I ...
3	EUCTR2020-003653-30-ES (EUCTR)	26/07/2021	15/12/2021	A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsenin Ambulan ...	A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsenin Ambulan ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: NS-065/NCNP-01 INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	20	Phase 2	United States;Spain;Turkey;Russian Federation;Italy;China
4	NCT04956289 (ClinicalTrials.gov)	July 1, 2021	30/6/2021	Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsenin Ambulant and Non-Ambulant Bo ...	A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsenin Ambulan ...	Duchenne Muscular Dystrophy	Drug: Viltolarsen	NS Pharma, Inc.	Nippon Shinyaku Co., Ltd.	Recruiting	8 Years	N/A	Male	20	Phase 2	United States;Italy;Russian Federation;Spain;Turkey
5	EUCTR2021-000122-10-NL (EUCTR)	30/06/2021	08/04/2021	A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)	A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: NS-065/NCNP-01 INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	74	Phase 3	United States;Hong Kong;Taiwan;Greece;Spain;Ukraine;Turkey;Chile;Russian Federation;United Kingdom;I ...
6	EUCTR2021-000122-10-ES (EUCTR)	15/06/2021	30/07/2021	A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)	A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: NS-065/NCNP-01 INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	74	Phase 3	United States;Hong Kong;Taiwan;Greece;Spain;Ukraine;Turkey;Chile;Russian Federation;United Kingdom;I ...
7	NCT04687020 (ClinicalTrials.gov)	June 10, 2021	16/12/2020	Long-term Use of Viltolarsenin Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) ...	Long-term Use of Viltolarsenin Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) ...	Duchenne Muscular Dystrophy	Drug: Viltolarsen	NS Pharma, Inc.	NULL	Enrolling by invitation	N/A	N/A	Male	16	Phase 4	United States;Canada
8	EUCTR2020-003653-30-IT (EUCTR)	08/06/2021	08/06/2021	This is an Open-label Study to evaluate the Safety, Tolerability, and Efficacy of Viltolarsenin Ambu ...	A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsenin Ambulan ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: [NS-065/NCNP-01] INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	20	Phase 2	United States;Spain;Turkey;Russian Federation;China;Italy
9	EUCTR2021-000122-10-IT (EUCTR)	26/04/2021	08/06/2021	A Phase 3 study of Viltolarsen in boys with Duchenne Muscular Dystrophy (DMD)	A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen ...	Duchenne Muscular Dystrophy (DMD) MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: ...	Product Name: Viltolarsen Product Code: [NS-065/NCNP-01] INN or Proposed INN: VILTOLARSEN	NS Pharma, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	74	Phase 3	United States;Hong Kong;Taiwan;Greece;Spain;Ukraine;Turkey;Chile;Russian Federation;United Kingdom;I ...
10	NCT04768062 (ClinicalTrials.gov)	April 13, 2021	19/2/2021	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)	A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen ...	Duchenne Muscular Dystrophy	Drug: Viltolarsen	NS Pharma, Inc.	Nippon Shinyaku Co., Ltd.	Enrolling by invitation	N/A	N/A	Male	74	Phase 3	Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Russian Federation;Spain;Turkey

First Previous1 2Next Last